Beijing GeneCradle Therapeutics Technology

Beijing GeneCradle Therapeutics Technology is a clinical-stage biotechnology company dedicated to the development of innovative gene therapy products using recombinant adeno-associated virus (rAAV) technology. Founded by experts in viral vector research, the company focuses on addressing unmet medical needs in rare genetic disorders, including neuromuscular, metabolic, and lysosomal storage diseases. GeneCradle's robust pipeline features several candidates in clinical trials, most notably treatments for Spinal Muscular Atrophy (SMA) and Pompe disease. The company maintains an integrated platform that spans from early-stage drug discovery and vector optimization to large-scale GMP manufacturing. By leveraging its proprietary AAV technology, GeneCradle aims to provide long-term, curative solutions for patients with life-threatening hereditary conditions.